Normal thoracic aortic diameter in Thai people by multidetector computed tomography.

OBJECTIVE: To determine the normal size of the thoracic aorta among Thai people. MATERIAL AND METHOD: The aortic diameter of 73 Thai males and 56 Thai females, in four age groups, were measured from thoracic Multidetector Computed Tomography (MDCT) images. Aortic size were analyzed and correlated by age, sex, and vertebral body. RESULTS: All showed normal aortic configuration, i.e. smooth tapering from aortic root to ascending and descending aorta. Mean aortic diameters were 3.12 cm at proximal ascending aorta, 2.95 cm at distal ascending aorta, 2.59 cm at mid arch, 2.33 cm at proximal descending aorta, 2.14 cm at distal descending aorta, and 2.03 cm at diaphragm. Males' aorta were larger than females, and all levels of the aorta were significantly enlarged with increasing age. Tapering of the vessel ratio of the ascending aorta/distal aorta at diaphragm was 1.5 without statistical significance. There was a weak correlation between aortic size and vertebral body at all levels. Comparing the size of the aorta to that of the vertebrae, the aorta was larger at the ascending part, equal at the mid arch and smaller at the descending part. CONCLUSION: Among the Northern Thai people, the average size of the aorta was determined at each level. It was found that aortic size is significantly dependent on age, sex, and vertebral body width.

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.

OBJECTIVE: To assess the activity and toxicity of cisplatin and irinotecan alternating with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). MATERIAL AND METHOD: Eligibility included chemo-naïve stage IIIB with malignant effusion and stage IV NSCLC patients with measurable disease and a good performance status. Twenty-four patients were enrolled into the present study. There were 19 males and 5 females with a median age of 58.5 years and the median performance status was 1. Ninety-six percent had stage IV disease. These patients received cisplatin at 80 mg/ m2 and irinotecan at 200 mg/m2 on day 1, followed by docetaxel at 75 mg/m2 on day 22, in 6-week cycle for a maximum of 3 cycles. RESULTS: Eight out of twenty-two evaluable patients obtained a partial response (36%). The median time to tumor progression was 6 months. The median survival time and 1-year survival rate were 10.4 months and 45% respectively. The most frequent severe toxicities were neutropenia, anemia, and diarrhea. Febrile neutropenia occurred in four patients (16%), and was the cause of treatment-related deaths in two (8%). Other nonhematologic toxicities were mild including nausea, vomiting, and skin rash. CONCLUSION: Alternating cisplatin and irinotecan with docetaxel, as used in the present study was feasible and demonstrated encouraging efficacy in patients with non-small cell lung cancer However, this approach appears to be more toxic, especially in myelosuppression, than in previous reports of the sequential use of the similar agents.

Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer.

The present study evaluated the efficacy and toxicity of paclitaxel and carboplatin with megestrol acetate for patients with stage IIIb and IV non-small cell lung cancer (NSCLC). Forty patients with no prior chemotherapy and Karnofsky performance status of > or = 60 were enrolled in the study. There were 18 males and 22 females with a median age of 57.5 years, and the median performance status was 70 per cent. Eleven cases were stage IIIb and 29 cases were stage IV. Twenty-five cases were adenoCA, 12 were squamous cell, 2 were large cell and one was undifferentiated NSCLC. These patients received paclitaxel 135 mg/m2 by intravenous infusion over 24 hours before carboplatin was given at AUC=6 by 2 hours infusion. Megestrol acetate 160 mg/day was given to all patients from day 2 to 14. This treatment produced partial remission in 12 of 39 evaluable patients (30.76%). Toxicity caused mild nausea, vomiting, myalgia, neuropathy, 20.95 per cent grade 3 neutropenia and 4.15 per cent grade 4 neutropenia. Grade 3 thrombocytopenia was 5.4 per cent, without grade 4. There were no statistically significant changes in weight, serum albumin, and quality of life throughout the cycle 1-6. Conclusion: The addition of megestrol acetate to chemotherapy benefitted these patients by minimizing constitute symptoms throughout the treatment period especially in the quality of life, weight loss and stabilized serum albumin.